Corvallis, Oregon 97331


Purpose:

Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.


Study summary:

The pharmacokinetics for [14C]-BaP and metabolites will be assessed by UHLPC-Accelerator Mass Spectrometry (AMS, Lawrence Livermore National Laboratory) in plasma and urine collected over 48 hours following oral doses of 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene. Metabolite profiles and kinetics of elimination are predicted to be consistent with a BaP physiologically based pharmacokinetic (PBPK) model developed by Pacific Northwest National Laboratory (PNNL). A non-smoker, not exposed occupationally, receives 270-700 ng of BaP daily; about 95% dietary. The WHO has set an estimated safe daily lifetime (70 year/70 Kg individual, cancer endpoint) exposure to BaP of 42-350 ng. This protocol represents de minimus risk.


Criteria:

Inclusion Criteria: - Age 21-65 (inclusive) - If female, must be post-menopausal or have had surgical sterilization to eliminate any possibility for fetal exposure - Willing to defer blood donation for one month before, throughout, and one month after completion of study activities - Willing to avoid consuming cruciferous vegetables, I3C or DIM supplements, smoked or cured meat or cheeses, or charcoal-grilled meats for 2 weeks prior to and during each study cycle (gas grilled foods acceptable) Exclusion Criteria: - Smoker (tobacco or other substances) or use of smokeless tobacco in past 3 months or living with smoker - Regular use of medications that affect gut motility or nutrient absorption (e.g. cholestyramine, sucralfate, orlistat, pro- or anti-motility agents) - History of gastrointestinal surgery (e.g. bariatric surgery, cholecystectomy) or gastrointestinal disorder (Crohn's disease, celiac disease, IBS, or colitis) - Current or history of kidney or liver disease - Prior high-dose 14C exposure from medical tests. (micro-dose 14C exposure not exclusionary) - Occupational PAH exposure (e.g. roofers, asphalt pavers, fire-fighters, etc.) - Regular use of indole-3-carbinol or DIM dietary supplements


NCT ID:

NCT03631667


Primary Contact:

David E Williams, PhD
Phone: 541-737-3277
Email: david.williams@oregonstate.edu


Backup Contact:

Email: sandra.uesugi@oregonstate.edu
Sandra Uesugi, RN, MS, BSN
Phone: 5417373594


Location Contact:

Corvallis, Oregon 97331
United States

David E Williams, PhD
Phone: 541-737-3277
Email: david.williams@oregonstate.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.